| 87 |
Antithrombotic Strategy in PCI and AF Patients: Updated Strategy |
Alan C. Yeung |
Nov. 27. 19 |
| 86 |
Antithrombotic Strategy in HBR Patients: Updated Strategy |
Joo-Yong Hahn |
Nov. 27. 19 |
| 85 |
Antithrombotic and Antiplatelet Choice in Complex PCI |
Duk-Woo Park |
Nov. 27. 19 |
| 84 |
[TCTAP A-093] Determinants of Self-Discontinuation of Secondary Prevention Medications by Coronary Heart Disease Outpatients: Focus on the Role of Erectile Dysfunction |
Muhamad Ali SK Abdul Kader |
Apr. 20. 15 |
| 83 |
[TCTAP A-001] Outcomes of 6 Months Versus 12 Months Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Biolimus or Durable Polymer Zotarolimus-Eluting Stents: OPTIMA-C Study and Optical Coherence Tomography Sub-Study |
Byoung Kwon Lee |
Apr. 20. 15 |
| 82 |
The Role of Triple Antiplatelet Therapy in Patients with High Risk |
Young-Hoon Jeong |
Jul. 22. 09 |
| 81 |
Tailoring Treatment to Risk in Antiplatelet Therapy |
Alexandra J. Lansky |
Jul. 22. 09 |
| 80 |
What Is the Optimal Duration of DAPT Following DES Treatment? |
David E. Kandzari |
Jul. 22. 09 |
| 79 |
Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib |
Roxana Mehran |
Jul. 22. 09 |
| 78 |
Strategic Approaches to Obtain Better and Earlier CV Outcome |
Weon Kim |
Jul. 22. 09 |
